Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans.
Zacharias. David G DG; Kim. Sung Gyun SG; Massat. Alfonso Eirin AE; Bachar. Adi R AR; Oh. Yun K YK; Herrmann. Joerg J; Rodriguez-Porcel. Martin M; Cohen. Pinchas P; Lerman. Lilach O LO; Lerman. Amir A
Key Findings
- Humanin levels are significantly higher in unstable, symptomatic carotid plaques compared to stable, asymptomatic ones
- Humanin co‑localizes with macrophages, smooth muscle cells, fibroblasts, dendritic cells, and inflammatory enzymes MMP2/MMP9
- Higher plaque instability is associated with more apoptosis, and humanin may be an endogenous protective response
Practical Outcomes
- Humanin could be a natural protective factor against plaque instability, but there’s no direct evidence that supplementing it will improve cardiovascular health. For now, biohackers should stick to proven strategies—diet, exercise, and established supplements—to manage atherosclerosis risk while awaiting more intervention studies on humanin.
Summary
The research shows that the naturally occurring peptide humanin is found at higher levels in unstable carotid artery plaques of patients who have had symptoms like strokes, and it appears in many cell types linked to inflammation and cell death. This suggests humanin might be part of the body’s response to plaque damage, but the study does not test taking the peptide as a treatment.
Abstract
The mechanism of atherosclerotic plaque progression leading to instability, rupture, and ischemic manifestation involves oxidative stress and apoptosis. Humanin (HN) is a newly emerging endogenously expressed cytoprotective peptide. Our goal was to determine the presence and localization of HN in carotid atherosclerotic plaques. Plaque specimens from 34 patients undergoing carotid endarterectomy were classified according to symptomatic history. Immunostaining combined with digital microscopy revealed greater expression of HN in the unstable plaques of symptomatic compared to asymptomatic patients (29.42±2.05 vs. 14.14±2.13% of plaque area, p<0.0001). These data were further confirmed by immunoblot (density of HN/β-actin standard symptomatic vs. asymptomatic 1.32±0.14 vs. 0.79±0.11, p<0.01). TUNEL staining revealed a higher proportion of apoptotic nuclei in the plaques of symptomatic patients compared to asymptomatic (68.25±3.61 vs. 33.46±4.46% of nuclei, p<0.01). Double immunofluorescence labeling revealed co-localization of HN with macrophages (both M1 and M2 polarization), smooth muscle cells, fibroblasts, and dendritic cells as well as with inflammatory markers MMP2 and MMP9. The study demonstrates a higher expression of HN in unstable carotid plaques that is localized to multiple cell types within the plaque. These data support the involvement of HN in atherosclerosis, possibly as an endogenous response to the inflammatory and apoptotic processes within the atheromatous plaque.
Study Information
pubmed
2012
2012-02-06T00:00:00.000Z
10.1371/journal.pone.0031065
43
73